Vaccine developer Vaxcyte stock soars on results of experimental pneumonia jab

The study results could put the vaccine in line to challenge those from Pfizer and Merck.

Source: bizjournals.com Health Care:Biotechnology headlines - October 24, 2022 Category: Biotechnology Authors: Ron Leuty Source Type: news